These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7656127)

  • 21. Erythropoietin & ESRD payments: a promising policy outcome?
    Roe W
    Nephrol News Issues; 1989 Sep; 3(9):34-5. PubMed ID: 2682270
    [No Abstract]   [Full Text] [Related]  

  • 22. Once again, ESAs are in the eye of the storm.
    Neumann ME
    Nephrol News Issues; 2013 Jan; 27(1):10. PubMed ID: 23431575
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients.
    Ofsthun NJ; Lazarus JM
    Blood Purif; 2007; 25(1):31-5. PubMed ID: 17170534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.
    Lefebvre P; Duh MS; Mody SH; Bookhart B; Piech CT
    Dis Manag; 2007 Feb; 10(1):37-45. PubMed ID: 17309363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EPO--one year later. Part II. Balancing the costs and benefits.
    Blagg C
    Nephrol News Issues; 1990 Jun; 4(6):22, 38. PubMed ID: 2119485
    [No Abstract]   [Full Text] [Related]  

  • 26. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
    Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
    Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Taking a subq approach to EPO: experience in the clinic.
    Wish J
    Nephrol News Issues; 2007 Oct; 21(11):68. PubMed ID: 17970511
    [No Abstract]   [Full Text] [Related]  

  • 28. Resource use and patient care associated with chronic kidney disease in a managed care setting.
    Robbins JD; Kim JJ; Zdon G; Chan WW; Jones J
    J Manag Care Pharm; 2003; 9(3):238-47. PubMed ID: 14613467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should patients get EPO subcutaneously?
    Wish JB
    Nephrol News Issues; 2006 Aug; 20(9):12. PubMed ID: 16916054
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost of treating predialysis patients with recombinant human erythropoietin.
    Durand-Zaleski I; Goldfarb B; Blum-Boisgard C; Drüeke T; Kreis H
    Nephrol Dial Transplant; 1993; 8(4):311-4. PubMed ID: 8390004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HCFA, Stark eye Medicare ESRD expenditures.
    Koska MT
    Hospitals; 1988 May; 62(10):84. PubMed ID: 3283025
    [No Abstract]   [Full Text] [Related]  

  • 32. Establishing and controlling chronic renal failure treatment costs. A pressing need.
    Martín Hernández R
    Nefrologia; 2011; 31(3):256-9. PubMed ID: 21629334
    [No Abstract]   [Full Text] [Related]  

  • 33. [Kidney dialysis and transplantation].
    Makó J
    Orv Hetil; 2000 Dec; 141(50):2749. PubMed ID: 11189682
    [No Abstract]   [Full Text] [Related]  

  • 34. Erythropoietin claims monitoring policy: implications for clinical practice.
    Messana T
    Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle.
    Fuller DS; Pisoni RL; Bieber BA; Port FK; Robinson BM
    Am J Kidney Dis; 2013 Dec; 62(6):1213-6. PubMed ID: 24140369
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of treatment costs between dialysis and transplantation.
    Eggers P
    Semin Nephrol; 1992 May; 12(3):284-9. PubMed ID: 1615249
    [No Abstract]   [Full Text] [Related]  

  • 37. Renal transplantation costs: an economic analysis and comparison with dialysis costs.
    Aranzabal J; Pérdigo L; Mijares J; Villar F
    Transplant Proc; 1991 Oct; 23(5):2574. PubMed ID: 1926487
    [No Abstract]   [Full Text] [Related]  

  • 38. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries.
    Leese B; Hutton J; Maynard A
    Pharmacoeconomics; 1992 May; 1(5):346-56. PubMed ID: 10146999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost comparison of in-center dialysis, home dialysis, and transplantation in the Nashville area.
    Thompson K
    Nephrol Nurse; 1980; 2(6):23-4. PubMed ID: 7003421
    [No Abstract]   [Full Text] [Related]  

  • 40. Who should be paying for vitamin D analogues--Medicare or the patients?
    Grotegut J
    Nephrol Nurs J; 2006; 33(3):345-6. PubMed ID: 16912996
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.